T1 mapping在乳腺病变评估中的诊断性能:一项初步研究
该前瞻性研究纳入103例参与者共108个乳腺病变(良性25个、恶性83个),行T1 mapping、DWI和DCE检查,由两名放射科医生独立勾画ROI并分析T1值和ADC值。恶性组T1值(1817.08 ms ± 126.64)高于良性组(1429.31 ms ± 167.66),差异有统计学意义(P < 0.001);T1值鉴别良恶性的AUC为0.69(95% CI: 0.55 - 0.82,P = 0.005),评估ER状态的AUC为0.75(95% CI: 0.62 - 0.87,P = 0.002)。T1 mapping有潜力作为影像生物标志物辅助鉴别乳腺良恶性病变及评估乳腺癌ER表达状态。
要点
- 恶性乳腺病变T1值(1817.08 ms ± 126.64)高于良性病变(1429.31 ms ± 167.66),差异有统计学意义(P < 0.001)。
- T1值鉴别乳腺良恶性病变的AUC为0.69(95% CI: 0.55 - 0.82,P = 0.005)。
- T1值评估乳腺癌ER状态的AUC为0.75(95% CI: 0.62 - 0.87,P = 0.002),ER(-)组T1值显著升高(P = 0.001)。
核心结论
- T1 mapping有潜力作为影像生物标志物,辅助鉴别乳腺良恶性病变及评估乳腺癌ER表达状态。
研究设计与样本
- 前瞻性研究,纳入103例参与者共108个乳腺病变(良性25个、恶性83个),行T1 mapping、DWI和DCE检查,两名放射科医生独立勾画ROI并分析T1值和ADC值,以ICC评估观察者间可靠性。
关键影像表现/征象
- 恶性组T1值为1817.08 ms ± 126.64,良性组为1429.31 ms ± 167.66,两组差异有统计学意义(P < 0.001)。
- ER(-)组T1值显著升高(P = 0.001)。
- T1值在HER2、Ki67、N状态及组织学分级各组间无显著差异。
- T1值与ER表达显著相关(P < 0.01),与PR表达相关(P = 0.03)。
诊断标准与关键数值
- T1值鉴别乳腺良恶性病变的AUC为0.69(95% CI: 0.55 - 0.82,P = 0.005)。
- T1值评估ER状态的AUC为0.75(95% CI: 0.62 - 0.87,P = 0.002)。
临床应用与阅片要点
- 作者认为T1 mapping有潜力作为影像生物标志物辅助鉴别乳腺良恶性病变及评估乳腺癌ER表达状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess T1 mapping performance in distinguishing between benign and malignant breast lesions and to explore its correlation with histopathologic features in breast cancer.
METHODS: This study prospectively enrolled 103 participants with a total of 108 lesions, including 25 benign and 83 malignant lesions. T1 mapping, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) were performed. Two radiologists independently outlined the ROIs and analyzed T1 and apparent diffusion coefficient (ADC) values for each lesion, assessing interobserver reliability with the intraclass correlation coefficient (ICC). T1 and ADC values were compared between benign and malignant lesions, across different histopathological characteristics (histological grades, estrogen, progesterone and HER2 receptors expression, Ki67, N status). Receiver operating characteristic (ROC) analysis and Pearson correlation coefficient (ρ) were performed.
RESULTS: T1 values showed statistically significant differences between benign and malignant groups (P < 0.001), with higher values in the malignant (1817.08 ms ± 126.64) compared to the benign group (1429.31 ms ± 167.66). In addition, T1 values significantly increased in the ER (-) group (P = 0.001). No significant differences were found in T1 values among HER2, Ki67, N status, and histological grades groups. Furthermore, T1 values exhibited a significant correlation (ρ) with ER (P < 0.01) and PR (P = 0.03). The AUC for T1 value in distinguishing benign from malignant lesions was 0.69 (95 % CI: 0.55 - 0.82, P = 0.005), and for evaluating ER status, it was 0.75 (95 % CI: 0.62 - 0.87, P = 0.002).
CONCLUSIONS: T1 mapping holds the potential as an imaging biomarker to assist in the discrimination of benign and malignant breast lesions and assessing the ER expression status in breast cancer.
引用
- Lian C, Zhuang L, Wang Z, et al. The diagnostic performance of T1 mapping in the assessment of breast lesions: A preliminary study. Eur J Radiol. 2024. PMID: 38941821. doi:10.1016/j.ejrad.2024.111589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。